echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Sequoia and Sequoia are betting on whether the neural intervention track can replicate the success of cardiovascular intervention.

    Sequoia and Sequoia are betting on whether the neural intervention track can replicate the success of cardiovascular intervention.

    • Last Update: 2020-09-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Text . . . Yang Xue "I didn't expect nerve intervention to catch fire so quickly, now it's all red fried chicken."
    " an investor who laid out nerve intervention two years ago told Arterial Network.
    's first-tier market data can support his feelings, according to the arterial orange database financing data, in June-August this year, three months, the field of neural intervention intensive six financing, of which five financing amounted to 100 million yuan, investment institutions including Gao wei capital, Sequoia China, CITIC Medical Fund and other well-known investment institutions.
    of nerve intervention in the first-level market is a chain reaction under which the minimally invasive intervention industry as a whole is favored.
    first half of this year, not only did several companies list in the heart of the secondary market, but share prices soared.
    's share price has been trading around HK$8 per share since it was listed in Hong Kong in 2010, and by August 16, 2020, micro-invas per share had reached HK$35 per share.
    and Peijia Medical has a market capitalisation of nearly $20 billion.
    , especially Among the patients involved in the cardiovascular field and neurotranscing double track, has given the market a new opportunity in the field of neural intervention.
    is still in the long-established field of neural intervention, is thought to be replicating the heart intervention of a decade ago, the market is expanding rapidly, and local companies are breaking ground.
    stage, China's neural intervention market is dominated by Medtron, Johnson and Johnson Healthcare, Stryker and other foreign-funded enterprises.
    accounts for more than 80 per cent of the market, and Medtron alone accounts for more than 60 per cent.
    the other side of the market from the minimally invasive Shentong, Peijia Medical, Tai Jieweiye, Chengtong Bridge, Heart Health and other enterprises are making efforts, from nothing to have to build a complete product line.
    we can expect an opportunity to replicate the domestic substitution success in the field of coronary intervention in the future.
    in the field of neural intervention, according to incomplete arterial network statistics, there are more than 20 enterprise layout.
    20 enterprises, including micro-invasive medical, Peijia Medical, Vixin Medical (owned by the Weigao Group) and other listed enterprises, including the top VC holdings, completed several rounds of large-scale financing of enterprises, such as to create a bridge, heart health care, Ake Medical.
    can be said that nerve intervention in domestic substitution is opening the golden age.
    point of view, the barriers in the field of neural intervention are high, the technology is complex, localization is more difficult than coronary intervention, and the completion of domestic substitution is not as simple as imagined.
    what kind of industrial changes are taking place under the urging of capital in the hot soil of neural intervention? The arterial network combs the neural intervention track.
    nerve intervention is mainly associated with cerebrovascular diseases, cerebrovascular diseases have been a common cause of death in China, china's annual cerebrovascular diseases more than a million new patients.
    according to the 2019 Health Statistics Yearbook, the number of discharges from public hospitals in 2018 reached 5.67 million, accounting for 6.48 percent of the disease's composition.
    more than 720,000 people had intracranial bleeding; 3.73 million had cerebral infarction; and 87,000 had arterial blockages and stenosis in the brain.
    in terms of disease costs, the per capita medical expenses of hospitals in the province of cerebral hemorrhage were 254.8 million yuan, and the cost of cerebral infarction was 14,117 yuan.
    in the field of minimally invascopic intervention, nerve intervention is known as the jewel in the crown of intervention surgery, which means that the field of neural intervention is very difficult.
    Neural intervention is supported by digital diatomy angiosis (DSA) system, using intravascular catheter operation technology, through selective effervescopy, embolism, dilation forming, mechanical removal, drug delivery and other specific methods, the lesions that affect the human neurovascular system are diagnosed and treated.
    neuro-interventional therapy is a method of treating neck or intracranial vascular disease by piercing the artery (or veins) and using special catheters to reach the neck or intracranial blood vessels.
    is more difficult to implement than cardiovascular intervention.
    structure, there are sinuses between the brain vein and the neck vein, which is a unique structure within the skull.
    cerebrovascular vessels than cardiovascular thinner, brain arteries fine, long, large bending, lack of elastic throbbing.
    , cardiovascular disease can be divided into pre-descending, swinging and right coronary arteries a total of 3.
    the cerebrovascular vessels are sent from the aortic bow, the vertebral arteries on both sides, the cervical arteries on both sides and the lower arteries in the collarbone on both sides, for a total of 6 blood vessels.
    in the complexity of the disease, cardiovascular intervention mainly uses stents to spread blood vessels to solve the problem of stenosis.
    but the symptoms of cerebrovascular disease are more complex and diverse, in addition to nerve intervention to solve the narrow problem, there are cerebrovascular formation of "bubble" aneurysms, as well as ischemic stroke.
    so neuro-intervention surgery on the product precision requirements are also higher, the requirements of the material is more fine, smooth, passability is also better.
    heart stents appeared in the 1970s and 1980s, and intracranial vascular stents only in 2002.
    the nerve intervention in our country started late, but the development is rapid.
    neurotransms were not well received until 2015, but are booming today.
    2015, China entered the 2.0 era of stroke treatment, and domestic neuroradiology intervention began to accelerate.
    In terms of scale and growth rate, according to the data from the Blue Book of Medical Devices of China, Frost Sullivan and the Fifth Annual Conference of the Neurotransience Branch of the Chinese Stroke Society (CINS2020), the market size of China's neuro-intervention devices in 2019 was 6.3 billion, with 40,000 cases of hydrants, with a compound growth rate of up to 30% in 2015-2019, and nerve intervention is ushering in a period of vigorous development.
    from an adaptive point of view, the main diseases in the field of neurological intervention include ishemia stroke, arterial stenosis and aneurysms, the first two are isomorphic diseases, aneurysms are hemorrhagic diseases.
    in the neuro-intervention market, the products are divided into three main categories: pathological, hemorrhage and isoemia.
    distribution of the main products corresponding to the disease species is shown below.
    "Because the incidence of ischemic stroke is higher, the market for hydrant products should be larger than the market for aneurysm intervention products, and the market share should be even dozens of times larger, " an industry insider told Arterial Network.
    " to the more developed French statistics of nerve intervention, stroke is the largest proportion of the market, followed by aneurysms and cerebral aneurysms, it is expected that china will also show this trend in the future.
    France 2019 neuro-intervention market share of different diseases at present, only foreign-funded enterprises can fully cover the three categories of product lines, some domestic enterprises can achieve a single disease product line coverage.
    analysis of the current situation of the main products of the neuro-intervention market, we can understand the distribution and layout of domestic enterprises in the neural intervention market.
    ischemic products are mainly associated with two major diseases: ischemic stroke and cerebral arterial stenosis.
    neuro-interventional treatment of ischemic stroke products mainly include hydrant stents, pumping hydrants and other products.
    hydrant stent in ischemic products, a micro-catheter that enters the brain through a leg indent to reach the arteries that cause stroke, removing the plaques that cause stroke and helping to restore blood flow.
    guidelines for the treatment of acute cerebral infarction, which were updated by China and the United States in 2015, are recommended at the highest level.
    international giants such as Medtron's Solitaire, Stryker's Trevo stent-picker, Penumbra bolt-picker, and Johnson and Johnson Medical's Revive SE stent system are the mainstream products in the market.
    's Trevo ProVue bolt-picker is the first fully visual bolt-picker on the market and is known as a bolt-picker.
    in the domestic echelon, is currently acquired by health care Nico medical bolting device has been listed.
    the Thrombite ™ (Dragon) bolting bracket, which was independently developed by Tsingtong Bridge, was certified as CE-certified by the European Union in March this year.
    "Yulong" has also entered the State Drug Administration (NMPA) CLASS III "innovative medical device" green channel products, has completed China's multi-center randomized controlled clinical trials, will soon be listed in China.
    hydrant stents of 18th-year-old PeiJiaGage and Cedric Medical are in clinical trials.
    the heart of the hydrant system to achieve the domestic first multi-point development bolt, is the only long-size bolting bracket.
    heart Kaino, long-term God Kang and other enterprises have also laid out the bolt bracket products.
    Sek Trevo ProVue hydrant-taking process The source of Strek's official website in addition to hydrant stents, thrombosis is also an important way to treat ischemic stroke.
    The main tool for pumping the thrombosis is the suction catheter or re-perfusion catheter, using the principle of negative pressure suction to reach the near end of the blood vessel of the thrombosis by the suction catheter or re-perfusion catheter, the thrombosis is sucked out.
    80 percent of ischemic stroke devices in the U.S. market today use a suction catheter first.
    industry believes that all the field of intervention supplies, according to the technical difficulty ranking, bracket, balloon, catheter difficulty is gradually increasing, the difficulty of implantation is greater than the difficulty of intervention.
    so the research and development and production of suction catheters is more difficult than the bolting bracket.
    major importers of pumped hydrant products include Medtron, Reon, Penumbra, all three of which have obtained domestic review registration certificates.
    Among domestic manufacturers, Warby Medical is studying suction catheters, and currently, Warby Medical's intracranial thrombosis suction catheters are applying for FDA and CE certification, and domestic registration has begun clinical trials at Xuanwu Hospital.
    second major disease in isoemia products is cerebrovascular stenosis, i.e. intracranial atherosclerosis stenosis, the main products are balloons and stents.
    For interventional treatment of intracranial atherosclerosis stenosis, arterial stents are generally delivered to vascular stenosis through balloon dilation catheters or treated directly by drug-washed balloons, and are suitable for patients with ischemic symptoms and stenosis greater than 50% or patients with no obvious symptoms but more than 70%.
    manufacturers of intracranial balloon expansion catheters include Sano Medical (documented), Cardiel Medical.
    intracranial drug ancranial ancranial ancranial ancranial anctication stents are now in the late stages of clinical life.
    hemorrhagic cerebrovascular diseases include intracranial aneurysms, cerebrovascular malformations and other diseases.
    In hemorrhagic diseases, intracranial aneurysms are high incidence and major diseases, according to clinical statistics, in cerebrovascular diseases, the incidence of intracranial aneurysms is second only to cerebral thrombosis and hypertension cerebral hemorrhage, ranked third, each year in China has more than 150,000 aneurysm patients.
    neuro-interventional therapy for aneurysms are spring rings and dense mesh stents.
    Medtrol AXIUM™PRIME removable spring ring Source Medtron official network spring ring is in embolism surgery, a micro-catheter inserted into the aneurysm cavity, and then with a push rod the spring ring through the micro-catheter into the aneurysm cavity, using the mechanical closure of the spring ring and the secondary thrombosis effect, the aneurysm isolated from the blood circulation of the carrier aneurysm, so as to achieve the purpose of anti-aneurysm rupture.
    2014-2018, the number of in-vasovascular spring ring embolism operations performed on brain aneurysms in China increased from 253,000 to 523,000, with a compound annual growth rate of 19.7%, and is expected to grow to 158,000 units in 2025, according to the
    Peijia Medical Prospectus.
    china's spring ring embolism market will reach 5.537 billion yuan by 2025.
    will grow at a compound annual rate of 14.2% from 2018 to 2025.
    china's intracranial aneurysm stent market is expected to expand to 812 million yuan in 2025, with a compound annual growth rate of 15.2 percent in 2018-2025.
    in the spring ring market, major import brands include Medtron's AXIUM, Johnson and Johnson's spring ring, and Stryker's Target spring ring.
    the price of the imported spring ring is between 1.5w and 2w.
    spring ring this equipment has been approved more domestic brands, including Pei Jiajiaqi, Vixin Medical, Tai Jieweiye, Warby Medical, etc. have been approved.
    the price of a domestic spring ring is less than 1w.
    addition to the spring ring, the dense mesh bracket is also a product that has received more attention.
    In present, the dense mesh stent is currently the international treatment of huge complex aneurysm advanced method, the secret network stent has a blood flow-oriented role, after placement can let the blood flow does not enter the aneurysm, aneurysm slowly solidified to form a blood clot and then disappear.
    Medtron PIPELINE™FLEX dense mesh bracket The most well-known product of Medtron's official network network bracket is Medtron's PIPELINE, pipeline first-generation products launched in 2013, is the earliest application of clinical blood flow guidance device.
    has now been upgraded to the third generation, which uses a phosphatidylcholine bioacceliable polymer (PC) coating to reduce thrombosis.
    in the field of dense mesh bracket products, domestic also have products that can play.
    minimally invasive tubridge mesh bracket (blood flow guide device) it broke the market monopoly of imported mesh bracket, with Medtron's PIPELINE dense mesh bracket and called the domestic secret mesh support market "double male."
    Keno, Ai ke medical, warm Yang medical and other start-ups at this stage of the core research products are also dense network bracket.
    As far as the product is concerned, the current product is still iterative, clinical existing dense mesh bracket can be improved, so for start-ups, as long as they can solve existing problems, there is room in the market.
    It is learned that the price of dense mesh stents in 18w-20w, the use of dense mesh stents in the domestic clinical is growing, the initial number of operations is not large, in the hospital to carry out more secret mesh stent surgery, Beijing Tiantan Hospital in 2016-2017 is expected to complete 300 cases of dense mesh stent surgery.
    In addition, the third category of neural intervention products, neural paths in the field of long-end channel catheters, micro-catheters, balloon guide tubes, etc. , including crucibles, formation catheters, finger guide tubes, intermediate catheters, blocking the compression system.
    mainly used for each.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.